Abstract
Migration of vascular smooth cells from the media to the intima essentially contributes to neointima formation after percutaneous transluminal angioplasty and stent implantation. The stable prostacyclin mimetic iloprost has been shown to inhibit neointima formation in experimental restenosis, but it is currently unknown whether this may be caused by an antimigratory effect. Hence, the present study analyses (i) the influence of G s-coupled prostacyclin (IP) receptors on cell migration and (ii) verifies whether EP 3 receptors with opposite (i.e., G i) coupling may conversely stimulate cell migration. In a modified Boyden chamber model, it was shown that iloprost dose-dependently inhibits the migration of primary human arterial smooth muscle cells, which constitutively express the IP receptor. On the other hand, human arterial smooth muscle cell migration was stimulated by the EP 3 receptor agonist M&B 28.767. To independently study the effects of these receptors, IP or EP 3 receptors were stably overexpressed in chinese hamster ovary cells (CHO-IP and CHO-EP 3). Chemotaxis of CHO cells transfected with G s-coupled IP receptors was concentration-dependently inhibited by iloprost (2–100 nM), while there was no effect of iloprost on mock-transfected CHO. By contrast, CHO-cells that overexpressed EP 3 receptors showed a significant, concentration dependent (1–100 nM) increase of cell migration in presence of the selective EP 3 agonist M&B 28.767. It is concluded that the prostacyclin mimetic iloprost inhibits vascular cell migration, which probably depends on a G s-mediated increase of intracellular cAMP. EP 3 receptors conversely stimulate CHO migration.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.